CD274 and colon carcinoma: The aptamer was conjugated at 5′ extremity with 40 kDa PEG to increase its in vivo half-life and successfully applied to suppress PD-1:PD-L1 interaction and growth of PD-L1-positive colon carcinoma cells in vivo, displaying a comparable efficacy to an antagonistic anti-PD-1 antibody.